Vepdegestrant: Difference between revisions
Content deleted Content added
→top: ce, rm orphan tag (Query 38614); ► Wikiproject Orphanage: You can help! ● |
Innerstream (talk | contribs) No edit summary Tag: nowiki added |
||
| Line 1: | Line 1: | ||
{{Infobox drug |
|||
| drug_name = |
|||
| INN = |
|||
| type = <!-- empty --> |
|||
| image = Vepdegestrant.svg |
|||
| alt = |
|||
| caption = |
|||
<!-- Clinical data --> |
|||
| pronounce = |
|||
| tradename = |
|||
| Drugs.com = |
|||
| MedlinePlus = |
|||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
| pregnancy_AU_comment = |
|||
| pregnancy_category= |
|||
| routes_of_administration = |
|||
| ATCvet = |
|||
| ATC_prefix = <!-- 'none' if uncategorised --> |
|||
| ATC_suffix = |
|||
<!-- Legal status --> |
|||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|||
| legal_AU_comment = |
|||
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 --> |
|||
| legal_BR_comment = |
|||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_CA_comment = |
|||
| legal_DE = <!-- Anlage I, II, III or Unscheduled --> |
|||
| legal_DE_comment = |
|||
| legal_NZ = <!-- Class A, B, C --> |
|||
| legal_NZ_comment = |
|||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> |
|||
| legal_UK_comment = |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
| legal_US_comment = |
|||
| legal_EU = |
|||
| legal_EU_comment = |
|||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
|||
| legal_UN_comment = |
|||
| legal_status = Investigational<!-- For countries not listed above --> |
|||
<!-- Pharmacokinetic data --> |
|||
| bioavailability = |
|||
| protein_bound = |
|||
| metabolism = |
|||
| metabolites = |
|||
| onset = |
|||
| elimination_half-life = |
|||
| duration_of_action= |
|||
| excretion = |
|||
<!-- Identifiers --> |
|||
| CAS_number = 2229711-68-4 |
|||
| UNII = WC1U3R1YMI |
|||
| PubChem = 134562533 |
|||
| DrugBank = |
|||
<!-- Chemical and physical data --> |
|||
| IUPAC_name = (3''S'')-3-[6-[4-<nowiki>[[</nowiki>1-[4-[(1''R'',2''S'')-6-Hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1''H''-isoindol-2-yl]piperidine-2,6-dione |
|||
| C = 45 | H = 49 | N = 5 | O = 4 |
|||
}} |
|||
'''Vepdegestrant''' is an experimental [[selective estrogen receptor degrader|estrogen receptor degrader]] that works via [[proteolysis targeting chimera]]. It is developed for advanced [[estrogen receptor]] positive breast cancer.<ref>{{cite journal |last1=Iwata |first1=H. |last2=Naito |first2=Y. |last3=Hattori |first3=M. |last4=Yoshimura |first4=A. |last5=Yonemori |first5=K. |last6=Aizawa |first6=M. |last7=Mori |first7=Y. |last8=Yoshimitsu |first8=J. |last9=Umeyama |first9=Y. |last10=Mukohara |first10=T. |title=58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study |journal=Annals of Oncology |date=November 2023 |volume=34 |pages=S1488–S1489 |doi=10.1016/j.annonc.2023.10.193}}</ref><ref>{{cite journal |last1=Iwata |first1=H. |last2=Hamilton |first2=E.P. |last3=Ma |first3=C.X. |last4=De Laurentiis |first4=M. |last5=Hurvitz |first5=S.A. |last6=Wander |first6=S.A. |last7=Danso |first7=M.A. |last8=Lu |first8=D.R. |last9=Perkins |first9=J. |last10=Liu |first10=Y. |last11=Tran |first11=L. |last12=Anderson |first12=S. |last13=Chappey |first13=C. |last14=Yang |first14=D.Z. |last15=Campone |first15=M. |title=73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3 |journal=Annals of Oncology |date=November 2023 |volume=34 |pages=S1493 |doi=10.1016/j.annonc.2023.10.207}}</ref> |
'''Vepdegestrant''' is an experimental [[selective estrogen receptor degrader|estrogen receptor degrader]] that works via [[proteolysis targeting chimera]]. It is developed for advanced [[estrogen receptor]] positive breast cancer.<ref>{{cite journal |last1=Iwata |first1=H. |last2=Naito |first2=Y. |last3=Hattori |first3=M. |last4=Yoshimura |first4=A. |last5=Yonemori |first5=K. |last6=Aizawa |first6=M. |last7=Mori |first7=Y. |last8=Yoshimitsu |first8=J. |last9=Umeyama |first9=Y. |last10=Mukohara |first10=T. |title=58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study |journal=Annals of Oncology |date=November 2023 |volume=34 |pages=S1488–S1489 |doi=10.1016/j.annonc.2023.10.193}}</ref><ref>{{cite journal |last1=Iwata |first1=H. |last2=Hamilton |first2=E.P. |last3=Ma |first3=C.X. |last4=De Laurentiis |first4=M. |last5=Hurvitz |first5=S.A. |last6=Wander |first6=S.A. |last7=Danso |first7=M.A. |last8=Lu |first8=D.R. |last9=Perkins |first9=J. |last10=Liu |first10=Y. |last11=Tran |first11=L. |last12=Anderson |first12=S. |last13=Chappey |first13=C. |last14=Yang |first14=D.Z. |last15=Campone |first15=M. |title=73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3 |journal=Annals of Oncology |date=November 2023 |volume=34 |pages=S1493 |doi=10.1016/j.annonc.2023.10.207}}</ref> |
||
| Line 5: | Line 63: | ||
[[Category:Selective estrogen receptor degraders]] |
[[Category:Selective estrogen receptor degraders]] |
||
[[Category:Piperidines]] |
|||
[[Category:Piperazines]] |
|||
[[Category:Butyramides]] |
|||
[[Category:Phenols]] |
|||
Revision as of 02:11, 14 December 2023
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C45H49N5O4 |
| Molar mass | 723.918 g·mol−1 |
Vepdegestrant is an experimental estrogen receptor degrader that works via proteolysis targeting chimera. It is developed for advanced estrogen receptor positive breast cancer.[1][2]
References
- ^ Iwata, H.; Naito, Y.; Hattori, M.; Yoshimura, A.; Yonemori, K.; Aizawa, M.; Mori, Y.; Yoshimitsu, J.; Umeyama, Y.; Mukohara, T. (November 2023). "58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study". Annals of Oncology. 34: S1488–S1489. doi:10.1016/j.annonc.2023.10.193.
- ^ Iwata, H.; Hamilton, E.P.; Ma, C.X.; De Laurentiis, M.; Hurvitz, S.A.; Wander, S.A.; Danso, M.A.; Lu, D.R.; Perkins, J.; Liu, Y.; Tran, L.; Anderson, S.; Chappey, C.; Yang, D.Z.; Campone, M. (November 2023). "73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3". Annals of Oncology. 34: S1493. doi:10.1016/j.annonc.2023.10.207.